Oslo, Norway, 14 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 8 January 2026 regarding the resolution by the Company’s extraordinary general meeting to carry out a reverse share split of the Company’s shares. Key information related to the reverse share split, including the relevant key … Read more
CEO Øystein Soug presented the company and participated at the YAFO Capital’s ACCESS ASIA BD Forum.
Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA (“Oncoinvent” or the “Company”) 31 October 2025 regarding the appointment of Ramzi Amri as the new CFO of the Company as of January 2026. The Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in the Company … Read more
Oslo, Norway, 8 January 2026: An extraordinary general meeting of the Company was held today, 8 January 2026, by electronic means through Lumi AGM. The general meeting, inter alia, resolved i) audited interim balance sheet, ii) a reverse share split, iii) a capital reduction, and iv) proxy to the Board of Directors. The complete minutes … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.